The Heart Attack Diagnostics Market is expected to
reach USD 15.4 billion by 2024, according to a new report by Grand View
Research, Inc. The heart attack diagnostics market is anticipated to witness a
lucrative growth during the forecast period from2016 to 2024. From 2001 to
2011, age-standardized, heart attack incidence rates have significantly
decreased worldwide. However, the overall risk factors and the disease burden
remains large, thereby rendering the heart attack diagnostic sectors a
profitable growth prospect.
This growth is attributed to a majority of factors,
such as high prevalence of coronary heart diseases, increased tobacco smoking,
and obesity, enhanced adoption of unhealthy diet is resulting in a high
cholesterol incidence in individuals, particularly in the rising geriatric
population. However, the low Medicare reimbursement provided for the mobile
cardiac outpatient telemetry electrocardiogram (ECG) and the progressively
declining heart attack incidence rates are expected to hamper the market
growth.
The heart attack diagnostics
market has been classified by product into electrocardiogram, which measures
the electrical activity of the heart; echocardiogram, a form of ultrasound test
that provides images of the heart; blood tests that measure the expression of
certain proteins in excess, such as troponin levels, and cardiac enzymes; and
other diagnostic products. The ECG segment is expected to witness a significant
growth rate in developing countries, owing to the technological advances
coupled with increasing applications of ECG. Although, the increasing demand
for cost effective, rapid blood tests such as troponin and Creatine Kinase MB
Isoenzyme (CK-MB) is likely to acquire major market share in the near future.
The key countries landscape
included in the report are U.S., Canada, Germany, UK, China, India, Brazil,
Mexico, South Africa, and Middle East. The Asia Pacific
region is anticipated to be the fastest growing region during the forecast
period. On the other hand, North America is estimated to dominate the global
heart attack diagnostics market.
Further key findings from the study suggest:
- North America is estimated to dominate the
global heart attack diagnostics market. The increasing awareness about
heart attacks, its causative and risk factors, and enhanced uptake and
acceptance of technologically advanced diagnostics is expected to
contribute to the market growth.
- The Asia Pacific region is expected to be the
fastest growing region during the forecast period. to The reason being the
considerably large burden of heart diseases in certain developing regions,
such as in India, where 2.4 million people die annually due to heart
diseases. As a result of the soaring incidences of heart diseases, an
urgent requirement to undertake awareness measures and incorporate
advanced diagnostics is expected to fuel the market growth.
- The troponin blood test type is the largest
grossing segment and is expected to capture the largest share in 2015,
especially in developing countries including Brazil, China, and India. Its
applications as a cardiac monitoring device and its indispensable use as a
heart attack diagnostic tool will be a contributing factor supporting the
market growth. The industry comprises of several local as well as global
players. Some of the major players of this industry include Siemens
Healthcare GmbH, Schiller AG, GE Healthcare, and Hitachi Medical
Systems.
Grand View Research has
segmented the heart attack diagnostics market on the basis of product and region:
Heart Attack Diagnostics Test Type Outlook (Revenue,
USD Million, 2013 - 2024)
- Electrocardiogram (ECG)
- Blood tests
- Troponin
- CK-MB
- Others
- Others
Heart Attack Diagnostics Regional Outlook (Revenue,
USD Million, 2013 - 2024)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- Middle East
- South Africa
No comments:
Post a Comment